17:38 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cervical cancer; lung cancer; ovarian cancer Patient sample, cell culture and mouse studies suggest promoting ATP5H expression or inhibiting reactive oxygen species (ROS) could help treat therapy-resistant cancers. In tumor samples from patients with cervical...
17:53 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cervical cancer; skin cancer Mouse studies suggest a vaccine based on a nanoparticle-HpV16gp2 peptide conjugate could help treat human papillomavirus (HPV)-associated cancers. The conjugate consists of nanoparticles with a polypropylene sulfide core and HpV16gp2 peptides...
18:57 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Vaxart's teslexivir misses in Phase II for anogenital warts

Vaxart Inc. (NASDAQ:VXRT) said twice-daily topical teslexivir (BTA074) 5% gel missed the primary endpoint of improving the complete clearance rate of baseline anogenital warts (condyloma) by week 16 vs. placebo in a Phase II trial...
18:53 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

FDA lifts hold on Phase I/II of axalimogene filolisbac for SCCHN

Advaxis Inc. (NASDAQ:ADXS) said FDA lifted a clinical hold on a Phase I/II combination study that includes the company's axalimogene filolisbac (ADXS11-001). The trial is evaluating the therapy in combination with PD-L1 inhibitor Imfinzi durvalumab to...
16:24 , Jul 13, 2018 |  BC Extra  |  Clinical News

Advaxis rises after FDA lifts clinical hold

Advaxis Inc. (NASDAQ:ADXS) jumped $0.12 (10%) to $1.34 Friday after it said FDA lifted a clinical hold on a Phase I/II combination study that includes the company's axalimogene filolisbac (ADXS11-001). The trial is evaluating the therapy...
15:12 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Kite reports data for TCR therapy in HPV-positive solid tumors

The Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD) reported data from seven evaluable patients with metastatic HPV-16-positive solid tumors in the NCI-sponsored Phase I 16-C-0154 trial showing that a single infusion of a...
22:10 , Jun 4, 2018 |  BC Extra  |  Clinical News

Kite reports data for TCR therapy in HPV-positive solid tumors

The Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD) reported data from seven evaluable patients with metastatic HPV-16-positive solid tumors in the NCI-sponsored Phase I 16-C-0154 trial showing that a single infusion of a...
17:11 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

FDA places hold on Advaxis' combo trial

Advaxis Inc. (NASDAQ:ADXS) said FDA placed a clinical hold on a Phase I/II trial of axalimogene filolisbac (ADXS11-001) in combination with PD-L1 inhibitor Imfinzi durvalumab to treat HPV-related cancers. According to the company, the hold is...
17:07 , Mar 13, 2018 |  BC Extra  |  Financial News

Clinical hold sinks Advaxis shares

Advaxis Inc. (NASDAQ:ADXS) tumbled $0.26 (12%) to $1.95 on Tuesday after the company announced late Monday that FDA had placed a clinical hold on a Phase I/II trial of axalimogene filolisbac (ADXS11-001) (see BioCentury Extra,...
23:33 , Mar 12, 2018 |  BC Extra  |  Clinical News

FDA places hold on Advaxis' combo trial

Advaxis Inc. (NASDAQ:ADXS) fell $0.49 (22%) to $1.72 in after-hours trading Monday after it said FDA placed a clinical hold on a Phase I/II trial of axalimogene filolisbac (ADXS11-001) in combination with PD-L1 inhibitor Imfinzi...